文献速递肿瘤 PET/CT

18F-FAPI-04 PET/CT用于评估胰腺癌全身治疗患者的病理缓解

[18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-16

研究纳入59例胰腺癌患者,其中28例全身治疗后手术,分析基线及术前18F-FAPI-04 PET/CT参数与病理治疗反应(CAP评分)的关联。基线参数与CAP评分无相关性,但治疗前后FAPI摄取变化较大与更好的病理缓解相关,可能有助于预测生存及筛选转化手术候选者。

要点

  • 基线FAPI PET参数与胰腺癌病理治疗反应无显著相关。
  • 治疗后MTV和TLF在所有患者中显著降低。
  • FAPI摄取变化较大与更好的病理缓解相关。

核心结论

  • 治疗过程中FAPI摄取变化较大与胰腺癌患者更好的病理治疗反应相关,可能有助于预测延长生存。
  • 这些结果对于全身治疗期间筛选转化手术候选者具有临床意义。

研究设计与样本

  • 研究纳入59例胰腺癌患者,自2021年8月起入组,其中28例在全身治疗后接受手术治疗。
  • 采用美国病理学家协会(CAP)评分评估病理治疗反应,分析基线FAPI摄取与CAP评分的相关性。
  • 14例患者术前PET/CT扫描用于评估治疗前后FAPI摄取变化及其与病理治疗反应的关系。
  • 多重免疫组化(mIHC)分析用于识别FAPI在胰腺癌肿瘤中的生物分布。

主要发现

  • SUVmax与胰腺癌组织中FAP表达呈正相关。
  • 基线FAPI PET变量与CAP评分之间无相关性。
  • 治疗导致所有患者MTV和TLF显著降低。
  • 病理治疗反应良好(CAP评分≤2)患者的基线SUVmax和SUVmean与治疗后不同(p=0.001)。
  • FITC-FAPI探针显示癌相关成纤维细胞(CAFs)和肿瘤细胞具有相似的FITC-FAPI荧光强度,提示肿瘤消退与18F-FAPI-04摄取呈负相关。

关键数值与推荐

  • 病理治疗反应采用CAP评分评估,良好病理治疗反应定义为CAP评分≤2。
  • FAPI PET变量包括SUVmax、SUVmean、代谢肿瘤体积(MTV)和总病灶FAP表达(TLF)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study the association between [18F]FAPI- 04 uptake on positron emission tomography/computed tomography (PET/CT) and pathologic treatment response (PTR) in patients with pancreatic cancer (PC). METHODS: We enrolled 59 patients from August 2021, of whom 28 underwent surgical treatment after systemic therapy. The patients were investigated for a correlation between baseline fibroblast activation protein inhibitor (FAPI) uptake and PTR using College of American Pathologists (CAP) scores. The FAPI PET variables include standardised uptake value (SUV)max, SUVmean, metabolic tumour volume (MTV), and total lesion FAP expression (TLF). A PET/CT scan obtained before surgery in 14 patients facilitated assessing changes in FAPI uptake through treatment, and their association with PTR. Multiplex immunohistochemistry (mIHC) analysis identified the FAPI biodistribution in the PC tumours. RESULTS: The SUVmax correlated positively with FAP expression in PC tissues. However, there was no correlation between baseline variables and the CAP scores. Treatment resulted in remarkably reduced MTV and TLF in all patients. The baseline SUVmax and SUVmean of patients with a good PTR (CAP score ≤ 2) differed from those after treatment (p = 0.001). An FITC-FAPI probe intuitively showed that cancer-associated fibroblasts (CAFs) and tumour cells had a similar FITC-FAPI fluorescence intensity, indicating a negative association between tumour regression and [18F]FAPI- 04 uptake. CONCLUSION: Greater changes in FAPI uptake through treatment were associated with a better PTR in patients with PC and might be valuable in predicting prolonged survival. These results are clinically meaningful when selecting candidates for conversion surgery during systemic treatment.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li X, Lu N, Sun K, et al. [18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Eur J Nucl Med Mol Imaging. 2025. PMID: 40237796. doi:10.1007/s00259-025-07271-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。